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To the Editor: Neisseria meningitidis is an exclusive human pathogen 
causing serious disease worldwide resulting in rapid mortality, and 
is associated with large epidemics every 5 - 10 years. It remains 
a leading cause of bacterial meningitis in children and young 
adults.1 Person-to-person spread of N. meningitidis can result in 
community epidemics of bacterial meningitis with major public 
health consequences.2 We analysed the laboratory records of N. 
meningitidis from blood and/or cerebrospinal fluid for the year 2009 
and observed an increase in the number of serogroup B isolates from 
previous years.3 This has implications for vaccine use, as serogroup B 
is not included in the currently available quadrivalent vaccine.
Methods
We reviewed the laboratory records for January - December 
2009. A total of 13 patients were confirmed with meningococcal 
disease. Diagnosis of N. meningitidis was by its characteristic Gram 
stain morphology, oxidase reaction and rapid latex agglutination 
(Wellcogen N. meningitidis ACYW135). The NH API (Biomerieux, 
South Africa) test was also used for confirmation. Serogrouping 
was performed at the National Institute for Communicable Diseases 
using slide agglutination with polyclonal antisera to capsular 
polysaccharide A, C, X, Y, Z, and W135 and monoclonal antiserum 
to capsular polysaccharide B (Remel, Biotech Limited, Dartford, UK). 
Isolates that had become non-viable on sub-culture were serogrouped 
via PCR.4
Results
Table I provides patient data, serogroups, antimicrobial profile and 
clinical outcome; 7 were males; age range was from a 30-day-old 
infant to a 34-year-old adult; 5 (39%) isolates were serogroup B, and 
4 (31%) were serogroup W135.
Most (12/13) isolates were fully susceptible to penicillin (≤0.06 mg/
ml); one was intermediately resistant (MIC, 0.125 mg/ml) belonging 
to serogroup B. All tested isolates were susceptible to ceftriaxone. 
None produced beta-lactamase. Seven (70%) isolates were resistant to 
cotrimoxazole with MIC values of 2 - 4 μg/ml. All isolates remained 
fully susceptible to rifampicin and ciprofloxacin by disc diffusion. The 
isolate that was intermediately resistant to penicillin was also resistant 
to cotrimoxazole (MIC, 2 μg/ml) but fully susceptible to rifampicin and 
ciprofloxacin. The case fatality rate was 27% (3/11) with known clinical 
outcome. Patient 2 isolate was from a post-mortem CSF specimen, 
patient 12 died 5 days post-admission and patient 13 died at the time 
of admission. Outcome was not known for patients 1 and 6 as hospital 
records were not traceable. Ceftriaxone was administered for 10 days 
for the patients who had a favourable outcome.
Discussion
In South Africa during 2006 - 2009, the predominant serogroup in all 
age groups was W135, with serogroup B the second most common.3 
Serogroup B caused peaks in disease in the Western Cape in 1979 
and 1988, and was also the predominant serogroup in Johannesburg 
during 1980 - 1982, with more than 60% of disease in children.5,6 
Meningococcal disease is characterised by sporadic cases throughout 
the year with occasional small clusters and a definite seasonal increase 
in winter and early spring.6 In our study, serogroup B was the more 
common type, and only one isolate (MIC, 0.125 μg/ml) belonging 
to serogroup B had decreased susceptibility to penicillin. The 
recommended first-line drug of choice for proven meningococcal 
septicaemia is intravenous benzyl penicillin, with ceftriaxone or 
cefotaxime as empiric therapy for suspected bacterial meningitis.6 
The emergence of drug-resistant meningococcus is increasingly 
worrisome.7 As ceftriaxone, ciprofloxacin and rifampicin are the 
recommended agents for chemoprophylaxis,6 they have remained 
fully susceptible as demonstrated in this study. Consequently, their 
continued use is supported as the main aim is to prevent secondary 
cases by eliminating nasopharyngeal carriage.
Of the 13 patients, 6 were <5 years old; the remainder ranged 
from adolescents to young adults, in keeping with global trends.8 
Vaccination in these age groups therefore is paramount to prevent 
severe disease and mortality.
To conclude, we showed an increase of serogroup B disease in the 
Pretoria region; the need for ongoing monitoring of antimicrobial 
susceptibility; the value of ceftriaxone for favourable therapeutic 
outcome; and that the isolates were fully susceptible to the agents 
commonly used for chemotherapy viz. ceftriaxone, ciprofloxacin and 
rifampicin.
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We report on 13 patients diagnosed with meningococcal infections 
in patients attending state-owned hospitals serving an indigent 
population in Pretoria in 2009. The case fatality rate was 27%. 
Ceftriaxone was the main antibiotic (9 out of 13 patients) for therapy. 
Five isolates (39%) were serogroup B and 4 (31%) serogroup W135. 
Most isolates (12/13) were fully susceptible to penicillin (MIC range 
0.016 - 0.047 μg/ml). A single isolate was intermediately resistant 
to penicillin (MIC, 0.125 μg/ml) while all isolates were uniformly 
susceptible to ceftriaxone, ciprofloxacin and rifampicin. This 
pattern reveals a shift in serogroups with an increase of serogroup B 
disease in the Pretoria region, and the need for ongoing monitoring 
of antimicrobial susceptibility profiles and the value of ceftriaxone 
for favourable therapeutic outcome.
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Table I. Characteristics of Neisseria meningitidis isolates and patient information (N=13)
Patient 
No. Age Gender Specimen Serogroup
PEN
mg/ml
CTR
mg/ml
COT
mg/ml
RIF
mm
CIP
mm
Antibiotic 
administered
Clinical 
outcome
1 1 mo. M CSF + blood B 0.047 0.002 2 29 35 Cefotaxime Not known
2 16 yrs F CSF C* NT NT NT NT NT Not known Died
3 3 yrs F CSF A 0.016 0.002 2 32 37 Ceftriaxone Discharged
4 2 yrs M Blood W135 0.032 0.002 4 31 35 Ceftriaxone Discharged
5 21 yrs F Blood W135 0.032 0.002 4 36 38 Ceftriaxone Discharged
6 24 yrs F CSF Y 0.016 0.002 0.004 36 39 Not known Not known
7 1 yrs M Blood W135 0.047 0.002 0.750 34 41 Ceftriaxone Discharged
8 16 yrs M CSF + blood B 0.032 0.002 0.064 33 37 Ceftriaxone Discharged
9 34 yrs M CSF W135 0.023 0.003 2 35 36 Ceftriaxone Discharged
10 4 mo. M Blood B 0.047 0.002 0.016 34 38 Ceftriaxone Discharged
11 24 yrs F CSF B 0.032 NT NT NT NT Ceftriaxone Discharged
12 19 yrs M CSF A* 0.032 NT NT NT NT Ceftriaxone Died
13 2 yrs F CSF B* 0.125 0.002 2 28 36 NIL Died
NT = not tested; PEN = penicillin; CTR = ceftriaxone; COT = cotrimoxazole; RIF = rifampicin; CIP = ciprofloxacin; µg/ml = micrograms per ml (MIC value); mm = millimeters (zone diameter 
size).
*Serogroup by PCR because of non-viable isolates.
October 2011, Vol. 101, No. 10  SAMJ738
